Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib with Oxaliplatin and Capecitabine in Advanced Pancreatic and Biliary Carcinoma
NCT00634751Phase 2Completed
- Sponsor
- University of Wisconsin–Madison
- Start
- Feb 2008
- Primary completion
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sorafenib in pancreatic adenocarcinoma (PDAC), biliary tract adenocarcinoma, sponsored by University of Wisconsin–Madison. Started Feb 2008; status: completed.
02
Drugs
sorafenib
03
Conditions
pancreatic adenocarcinoma (PDAC)biliary tract adenocarcinoma
Beyond the preview
Go deeper on NCT00634751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00634751.